1620673-99-5

Upstream product

• 1620673-11-1 4-{8-amino-3-[(6R,8aS)-3-oxooctahydroindolizin-6-yl]imidazo[1,5-a]pyrazin-1-yl}-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide 
• 79-22-1 methyl chloroformate 
• 1620675-70-8 (6R,8aS)-6-(8-chloroimidazo[1,5-a]pyrazin-3-yl)hexahydroindolizin-3(2H)-one 
• 1620675-71-9 (6R,8aS)-6-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)hexahydroindolizin-3(2H)-one 
• 5470-70-2 Methyl 6-methylnicotinate 
• 1620675-63-9 (E)-methyl 6-(3-ethoxy-3-oxoprop-1-en-1-yl)nicotinate 
• 1620675-64-0 methyl 6-(3-ethoxy-3-oxopropyl)piperidine-3-carboxylate 
• 1620675-65-1 methyl 3-oxooctahydroindolizine-6-carboxylate 
• 1620675-67-3 (6R,8aS)-3-oxooctahydroindolizine-6-carboxylic acid 
• 1620675-69-5 (6R,8aS)-N-((3-chloropyrazin-2-yl)methyl)-3-oxooctahydroindolizine-6-carboxamide 
• 1620675-62-8 (6R,8aS)-6-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)hexahydroindolizin-3(2H)-one 

Relevant academic research and scientific papers

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.